Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBINASDAQ:RUBYNYSE:SQZNASDAQ:TCBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsSQZSQZ Biotechnologies$0.03$0.03$0.25▼$3.56$826K2.34455,220 shsN/ATCBPTC Biopharm$0.68-55.8%$0.68$0.50▼$160.00$279K0.01157,979 shs5.33 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%SQZSQZ Biotechnologies0.00%0.00%0.00%0.00%-37.78%TCBPTC Biopharm0.00%0.00%0.00%0.00%-99.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIBrickell BiotechN/AN/AN/AN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIBrickell Biotech 0.00N/AN/AN/ARUBYRubius Therapeutics 0.00N/AN/AN/ASQZSQZ Biotechnologies 0.00N/AN/AN/ATCBPTC Biopharm 3.00Buy$48.006,948.46% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIBrickell Biotech$4.64M0.00N/AN/A$9.75 per share0.00RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ASQZSQZ Biotechnologies$18.16M0.05N/AN/A$1.94 per share0.01TCBPTC Biopharm$4.76M0.06N/AN/A$519.58 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIBrickell Biotech-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ASQZSQZ Biotechnologies-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/ATCBPTC Biopharm-$7.35MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIBrickell BiotechN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIBrickell BiotechN/A6.366.36RUBYRubius TherapeuticsN/AN/AN/ASQZSQZ BiotechnologiesN/A3.503.50TCBPTC Biopharm0.671.12N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIBrickell BiotechN/ARUBYRubius TherapeuticsN/ASQZSQZ Biotechnologies38.51%TCBPTC Biopharm16.25%Insider OwnershipCompanyInsider OwnershipBBIBrickell Biotech4.53%RUBYRubius Therapeutics5.30%SQZSQZ Biotechnologies16.00%TCBPTC Biopharm15.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIBrickell Biotech162.87 million2.74 millionNot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableSQZSQZ Biotechnologies1,62029.49 million24.77 millionNot OptionableTCBPTC Biopharm80410,00028,000Not OptionableRUBY, BBI, SQZ, and TCBP HeadlinesRecent News About These CompaniesTC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical ReviewJune 14, 2025 | americanbankingnews.comTC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) PatientJune 11, 2025 | prnewswire.comTC BioPharm Holdings PLC (TCBPY)May 11, 2025 | investing.comTCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T CellsApril 9, 2025 | finance.yahoo.comTC BioPharm: TCBP Announces Transition from Nasdaq to OTC MarketsMarch 24, 2025 | finanznachrichten.deTC BioPharm to be delisted from Nasdaq, moves to OTC MarketsMarch 23, 2025 | uk.investing.comTC Biopharm announces transition to OTC Markets from NasdaqMarch 22, 2025 | markets.businessinsider.comTC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses FrustrationMarch 21, 2025 | msn.comTC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting NoticeMarch 21, 2025 | tipranks.comTCBP Announces Transition from Nasdaq to OTC MarketsMarch 21, 2025 | prnewswire.comTC Biopharm launches cost reduction initiativesMarch 19, 2025 | finance.yahoo.comTCBP Announces Outsourcing Initiatives, Reducing Burn Rate and OverheadMarch 18, 2025 | prnewswire.comTC BioPharm: TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | finanznachrichten.deTCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | prnewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for WeekFebruary 28, 2025 | msn.comTCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO ForumFebruary 20, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | finanznachrichten.deTCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical TrialFebruary 11, 2025 | finanznachrichten.deTC Falls Despite Cohort B TrialsFebruary 11, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRUBY, BBI, SQZ, and TCBP Company DescriptionsBrickell Biotech NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.SQZ Biotechnologies NYSE:SQZ$0.03 0.00 (0.00%) As of 06/20/2025SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.TC Biopharm NASDAQ:TCBP$0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
